glp-1 and addiction Not just obesity: receptor agonists advance on Prospects of GLP-1 Therapies for

Weight loss is known to trigger compensatory biology: Increased appetite signaling Reduced resting energy expenditure Heightened food reward sensitivity Stopping GLP-1 therapy at peak dose, without tapering and without reinforcing lifestyle strategies at the exact moment hunger returns, does not allow lifestyle behaviors to take over. Emerging real-world data and obesity physiology suggest a different, more clinically relevant path: Gradual dose reduction rather than abrupt cessation Continued, structured dietary and exercise support Active monitoring during the high-risk post-cessation period We still need randomized trials designed specifically to test tapering and lifestyle-anchored maintenance strategies

Try the GLP-1 Support Stack today

To Use: Select an area of skin

The second study analyzed the effect of a monoclonal antibody that inhibits muscle mass loss, but found limited benefit